Name Nicholas Lydon | ||
 | ||
Born 27 February 1957 (age 67) ( 1957-02-27 ) Institutions Amgen
Schering-Plough
Ciba-Geigy Alma mater University of Leeds (BSc)
University of Dundee (PhD) Thesis Studies on the hormone-sensitive adenylate cyclase from bovine corpus luteum (1982) Known for Gleevec
AnaptysBio
BluePrint Medicines Education University of Leeds, University of Dundee Awards Lasker-DeBakey Clinical Medical Research Award Notable awards Lasker Award, Japan Prize, Royal Society | ||
Nicholas B. Lydon FRS (born 27 February 1957) is a British scientist and entrepreneur. In 2009 he was awarded the Lasker Clinical Award and in 2012 the Japan Prize for the development of Gleevec, a selective BCR-ABL inhibitor for the treatment of chronic myeloid leukaemia (CML), which converted a fatal cancer into a manageable chronic condition.
Contents
Education
Dr Lydon was educated at Strathallan School near Perth, Scotland. He earned a Bachelor of Science degree in biochemistry from the University of Leeds, England in 1978 and received his PhD in biochemistry from the University of Dundee, Scotland in 1982.
Career
In 1982 Dr Lydon accepted a position with Schering-Plough based in France as Charge de Recherche. Three years later he moved to Switzerland to work with Ciba-Geigy Pharmaceuticals, with whom he developed Gleevec. In 1997 he established Kinetex Pharmaceuticals in Boston which was acquired by Amgen in 2000, with whom he worked until 2002. Thereafter, he established several companies that continue to develop drugs to treat various conditions.
Honours and awards
Lydon's nomination for the Royal Society reads: